LSPG(SZ:301111)2024-04-21 07:42Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total of 160,000,000 shares[3]. - The company has no plans for stock distribution or capital increase through capital reserves for the current reporting period[3]. - The company implemented a cash dividend policy, distributing 16,000,000 CNY, which represents 100% of the total profit distribution[137]. - The cash dividend per 10 shares is 1.00 CNY, with no bonus shares issued[137]. - The total undistributed profits as of December 31, 2023, amounted to 177,884,501.43 CNY[138]. Financial Performance - The company's operating revenue for 2023 was ¥292,397,132.03, representing a 3.20% increase compared to ¥283,336,348.33 in 2022[17]. - The net profit attributable to shareholders for 2023 was ¥33,501,697.88, a slight increase of 0.25% from ¥33,417,538.99 in 2022[17]. - The net profit after deducting non-recurring gains and losses decreased by 9.20% to ¥23,623,155.29 from ¥23,989,911.12 in 2022[17]. - The net cash flow from operating activities was negative at -¥12,799,223.82, a significant decline of 118.32% compared to ¥69,879,889.67 in 2022[17]. - Total assets at the end of 2023 were ¥855,535,468.09, a decrease of 0.18% from ¥857,063,372.44 at the end of 2022[17]. Audit and Compliance - The company has appointed Huaxing Accounting Firm as its auditor for the reporting period[16]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[3]. - The company’s management team has acknowledged the legal responsibility for the accuracy of the annual report[3]. - The company maintained compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange throughout the reporting period[128]. Research and Development - Research and development (R&D) expenditure amounted to 8,441,854.30 yuan in 2023, representing 2.89% of operating revenue, down from 3.23% in 2022[59]. - The number of R&D personnel increased by 15.69% to 59 in 2023, with a notable rise in the 30-40 age group by 90%[59]. - The company is developing a classic Chinese medicine formula, with the project currently in the extraction phase of the pilot study[57]. - The project aims to achieve a successful development and registration of the new drug, which could lead to significant economic growth for the company[57]. Market Position and Brand Recognition - The company’s traditional Chinese medicine product, "Gujin Bujin Wan," was recognized as a non-material cultural heritage in Shantou City in April 2023, enhancing its brand value[31]. - The "Wannianqing" brand was included in the Guangdong Province Key Trademark Protection List in May 2023, indicating strong brand recognition[31]. - The company was recognized as a national "Chinese Time-honored Brand" in February 2024, further solidifying its market position[31]. - The company emphasizes innovation and quality, with a history dating back to 1891, establishing a strong brand image in the pharmaceutical manufacturing industry[28]. Supply Chain and Production - The company has established a procurement department to manage the supply of materials, aiming to reduce costs while ensuring quality[34]. - The company adheres to GMP standards in production, implementing a sales-driven production planning management system[35]. - The company is actively developing new products and technologies, focusing on innovative drugs and medical institution preparations[33]. - The company has a strategic focus on core therapeutic areas, ensuring a diversified and sustainable product pipeline[33]. Governance and Risk Management - The company has established a scientifically designed and effective internal control system, enhancing risk management and internal control environment[139]. - The internal control evaluation report indicates that 100% of the total assets and operating income of the evaluated units are included in the consolidated financial statements[141]. - The company has a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability in its operations[105]. - The company is enhancing its governance structure and risk management processes to improve operational resilience and adaptability[98]. Shareholder Relations and Commitments - The company actively engages with investors through various channels to maintain good relationships and enhance information transparency[107]. - The actual controller and shareholders of the company have committed to not transferring or managing their shares for 36 months post-IPO, ensuring stability in shareholding[149]. - The company has committed to strict adherence to share lock-up agreements, ensuring no sales of shares during the lock-up period[162]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders, ensuring transparency[164]. Employee Management - The total number of employees at the end of the reporting period was 522, with 195 in sales and 132 in production[133]. - The company has established a performance assessment management system linking employee salaries to company performance and key performance indicators[134]. - The company has a training plan focusing on new employee orientation, GMP training, and professional knowledge training[135]. Inventory and Production Adjustments - The inventory of liquid dosage forms rose by 78.24% to 128,953.61 liters, primarily due to a reduction in sales of certain products following changes in the medical insurance catalog[46]. - The production of granules and powders increased significantly by 44.23% to 39,893.85 kg, driven by the introduction of a new product line[47]. - The company reported a significant increase in inventory for granules and powders, up 185.21% to 7,381.10 kg, indicating production adjustments[47]. Related Party Transactions - The company has disclosed all related party transactions adequately, ensuring no false descriptions or significant omissions[151]. - The company will continue to reduce and avoid related party transactions with its subsidiaries, ensuring fair pricing and compliance with legal standards[151]. - The company has committed to avoiding any financial transactions with related parties outside of normal business operations, ensuring compliance with regulations set by the China Securities Regulatory Commission[153].